{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:12:26Z","timestamp":1739164346043,"version":"3.37.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/mjt.0b013e31818f9c68","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T15:35:56Z","timestamp":1242920156000},"page":"215-223","source":"Crossref","is-referenced-by-count":4,"title":["Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin"],"prefix":"10.1097","volume":"16","author":[{"given":"Jules I","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C","family":"Lasseter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"R2-3-20210202","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R3-3-20210202","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-3-20210202","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R5-3-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-000-0096-y","article-title":"Niacin dosing: relationship to benefits and adverse effects.","volume":"2","author":"Capuzzi","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R6-3-20210202","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth J Med"},{"issue":"12A","key":"R7-3-20210202","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"key":"R8-3-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903].","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"R9-3-20210202","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"R10-3-20210202","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"R11-3-20210202","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(81)92627-1","article-title":"Is cutaneous flushing prostaglandin mediated?","volume":"1","author":"Phillips","year":"1981","journal-title":"Lancet"},{"key":"R12-3-20210202","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/clpt.1985.170","article-title":"Prostaglandins and nicotinate-provoked increase in cutaneous blood flow.","volume":"38","author":"Wilkin","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"R13-3-20210202","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells.","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R14-3-20210202","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid.","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R15-3-20210202","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-3-20210202","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/00498250601175565","article-title":"The pharmacokinetics and disposition of MK-0524, a prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys.","volume":"37","author":"Chang","year":"2007","journal-title":"Xenobiotica"},{"key":"R17-3-20210202","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1.","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R18-3-20210202","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.bmcl.2007.03.058","article-title":"Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.","volume":"17","author":"Levesque","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"R19-3-20210202","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524).","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"R20-3-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"R21-3-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/dmd.106.011551","article-title":"Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.","volume":"35","author":"Dean","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R22-3-20210202","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.107.014696","article-title":"Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.","volume":"35","author":"Karanam","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R23-3-20210202","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bmcl.2006.10.055","article-title":"In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.","volume":"17","author":"Nicoll-Griffith","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"R24-3-20210202","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.clpt.6100345","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.","volume":"83","author":"Lai","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R25-3-20210202","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199106273242606","article-title":"Oral anticoagulant drugs.","volume":"324","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"R26-3-20210202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1657371","article-title":"Calibration of reference thromboplastins and standardisation of the prothrombin time ratio.","volume":"49","author":"Kirkwood","year":"1983","journal-title":"Thromb Haemost"},{"key":"R27-3-20210202","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0022-2143(96)90014-1","article-title":"Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio.","volume":"128","author":"Johnston","year":"1996","journal-title":"J Lab Clin Med"},{"key":"R28-3-20210202","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2165\/00003495-198325060-00004","article-title":"Drug interactions with warfarin.","volume":"25","author":"Serlin","year":"1983","journal-title":"Drugs"},{"key":"R29-3-20210202","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-199410050-00003","article-title":"Clinically significant drug interactions with the oral anticoagulants.","volume":"10","author":"Freedman","year":"1994","journal-title":"Drug Saf"},{"key":"R30-3-20210202","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"R31-3-20210202","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.tpj.6500308","article-title":"Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.","volume":"5","author":"Herman","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R32-3-20210202","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.","volume":"24","author":"Black","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"R33-3-20210202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem Res Toxicol"},{"key":"R34-3-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin.","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol Ther"},{"key":"R35-3-20210202","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/jm00300a041","article-title":"Mass spectral analysis in the identification of human metabolites of warfarin.","volume":"13","author":"Trager","year":"1970","journal-title":"J Med Chem"},{"key":"R36-3-20210202","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R37-3-20210202","first-page":"108","article-title":"Lipid-altering efficacy and tolerability profile of extended release niacin\/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia.","volume":"28","author":"Maccubbin","year":"2007","journal-title":"Eur Heart J"},{"key":"R38-3-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/009127009903900509","article-title":"Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.","volume":"39","author":"Van Hecken","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R39-3-20210202","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0091270002238772","article-title":"No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.","volume":"42","author":"Anderson","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R40-3-20210202","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1185\/030079907X188008","article-title":"Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.","volume":"23","author":"He","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R41-3-20210202","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2125.2006.02589.x","article-title":"Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.","volume":"61","author":"Ouellet","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R42-3-20210202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0091270006291622","article-title":"Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.","volume":"46","author":"Soon","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R43-3-20210202","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mcp.2000.112244","article-title":"The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin.","volume":"68","author":"Schwartz","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R44-3-20210202","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0091270004264164","article-title":"Absence of a pharmacokinetic interaction between etanercept and warfarin.","volume":"44","author":"Zhou","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-200905000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:44:36Z","timestamp":1739119476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200905000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31818f9c68","relation":{},"ISSN":["1075-2765"],"issn-type":[{"type":"print","value":"1075-2765"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}